Treatment of leg ulcers with GANIKDERMA® products
There are many definitions of leg ulcers of which are:
- Loss of epidermis and dermis around the knee or leg due to any cause which prevents healing (Moffat and Harper 1997)
- (leg ulcer) Chronic wounds occur due to conditions that predispose to decreased ability to maintain tissue integrity
(Davis et al. 1992)
- Leg ulcer is the loss of skin around the knee or foot which takes more than six weeks to heal (Dale et al. 1983)
The table below shows the causes of leg ulcers and frequency.
|Percentages are approximate|
Causes of venous leg ulcers
Any condition or calf muscle venous valves, prevents ability mechanism described above and, ultimately affecting calf health, because blood flow is inadequate.
This phenomenon occurs due to increased pressure in the veins (venous hypertension) and body requires a pressure gradient between arteries and veins to the heart to pump blood through the arteries and veins.
Eventually, integrity is affected tissue and skin lesions occur, due to minimal trauma and sometimes without any trauma.
Poor performance may be caused by venous valves:
- Varicose Veins
- Mechanical factors that cause obstruction of veins
Causes affecting calf muscle function are:
- Ankle immobility
Treatment of venous leg ulcers
Treatment should include the following:
- Evaluation of foot;
- Provide skin care;
- Nutritional support;
- Educate the patient;
- Products for wound management.
Precautions should be taken when compression therapy is:
- Compression bandage made of made of four layers should be made only after a full assessment of the patient and the wound;
- Compression is performed only by specialists.
Compression therapy should not be used in:
- Arterial leg ulcer;
- Patients with thrombosis;
- Patients with diabetes with severe disease;
- When index less than 0.83 ABPI (unless therapy is supervised by a specialist).
Patients with venous leg ulcer should be reviewed at regular intervals, to ensure that treatment is appropriate. Using compression tights is often allowed once the wound has healed completely (Dealey 2005).
Dressings used in the treatment of leg ulcers
The purpose of dressings used in the treatment of leg ulcers is to absorb exudate from the wound, to provide autolytic debridement (when the doctor deems necessary, surgical debridement can be done). Aims of debridement are to remove necrotic tissue from the wound.
Also, the dressing should provide a moist environment favorable for ulcer healing and prevent infection. Choice of dressing is done the same way as other types of wounds, according to the assessment, clinical, exudate level.
Treatment of venous leg ulcers with GANIKDERMA® products
According to Clinical Investigation (EN ISO 14155):
The cumulative area of leg ulcer wounds treated with GANIKDERMA® products was reduced by half following 30 days of treatment; after 57 days, 30.77% of the ulcerations healed completely, the others presenting good epithelization (with a cumulative area of 15% of the initial one).
The volume of those wounds was reduced by 50% after 6 days of treatment; following 39 days of treatment, the mean volume was 10% of the initial one, showing the great efficiency of the GANIKDERMA® products in the management of leg ulcers and diabetic foot.
During the treatment using GANIKDERMA® products no infection or foul odor were registered; the colorimetric assessment of the wound tissue (black – necrosis, black/brown dried/humid, yellow – fibrin, red – granulation tissue, pink – epithelium) during the healing process stands for the efficiency of GANIKDERMA® products in the treatment of the chronic wounds: in all the cases the black/yellow tissue turn in red/pink tissue due to the products’ fast and efficient debridement value, with no necrosis recurrence.
On the Wong-Baker scale, the mean value of pain level during GANIKDERMA® products dressing removal was 2.32 (ignorable pain). The dressing using GANIKDERMA® products were changed at 1.35 days (mean value); the health professionals mentioned the easiness of dressing appliance/removal, with no harm to the granulation/new epithelization tissue.